Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-27 | Michael A. Kelly has served as a member of the Board since December 2020. Mr. Kelly is a former senior executive of Amgen, Inc. and is currently acting as Founder & President of Sentry Hill Partners, LLC, a global life sciences transformation and management consulting business founded by Mr. Kelly in 2018. Mr. Kelly has more than two decades of executive experience as a senior leader in the life sciences industry serving in various strategic finance and operations positions at Amgen Inc. (NASDAQ: AMGN), most recently as Senior Vice President, Global Business Services and Vice President & CFO, International Commercial Operations. Mr. Kelly has also held positions at Biogen, Inc. (NASDAQ: BIIB), Tanox, Inc., and Monsanto Life Sciences, a division of the Nutrasweet Kelco Company. Currently, Mr. Kelly is an independent member of the Board of Directors for Aprea Therapeutics, Inc. (NASDAQ: APRE), DMC Global, Inc. (NASDAQ: BOOM), NeoGenomics, Inc. (NASDAQ: NEO), and Hookipa Pharma, Inc. (NASDAQ: HOOK). He also serves on the Council of Advisors and was the former audit committee chairman for Direct Relief, a humanitarian aid organization focused on health outcomes and disaster relief. Mr. Kelly holds a BSc in business administration from Florida A&M University, concentrating in Finance and Industrial Relations. |
| 2022-04-26 | Mr. Kelly holds a BSc in business administration from Florida A&M University, concentrating in Finance and Industrial Relations. |
| 2023-04-26 | Mr. Kelly holds a BSc in business administration from Florida A&M University, concentrating in Finance and Industrial Relations. |
| 2024-04-24 | Mr. Kelly holds a BSc in business administration from Florida A&M University, concentrating in Finance and Industrial Relations. |
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-02 | Michael A. Kelly Director Age 64 Committees: Audit, Risk Director Compensation Table: Michael A. Kelly $92,506. |
| 2022-03-31 | Michael A. Kelly Director Age 65 Independent Committees: Compensation, Corporate Governance and Nominating, Risk Mr. Kelly was appointed as a director in July 2020. |
| 2023-03-28 | Michael A. Kelly Director Age 66 Director since: 2020 Independent Committees: Compensation, Corporate Governance and Nominating, Risk Mr. Kelly was appointed as a director in July 2020. |
| 2024-04-02 | Mr. Kelly was appointed as a director in July 2020. He has more than two decades of executive experience in senior leadership roles in the life sciences industry. |
| 2025-04-01 | Mr. Kelly was appointed as a director in July 2020. He has more than two decades of executive experience in senior leadership roles in the life sciences industry. |
Data sourced from SEC filings. Last updated: 2026-02-03